PMCB

PharmaCyte Biotech, Inc. operates as a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Headquartered in Laguna Hills, California, the company specializes in a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box®. This platform encapsulates living cells in a protective coating, allowing them to be implanted in patients without triggering immune rejection. PharmaCyte's lead therapeutic candidate targets locally advanced, inoperable pancreatic cancer by encapsulating genetically modified cells that convert the chemotherapy prodrug ifosfamide into its active form directly at the tumor site. The company also pursues diabetes treatment applications using encapsulated insulin-producing cells. PharmaCyte holds exclusive worldwide rights to this technology for specific applications and maintains partnerships for clinical development. The company acquired its core encapsulation technology through licensing agreements and continues to advance its pipeline through clinical trials. As a development-stage enterprise, PharmaCyte generates no commercial revenue and focuses resources on research, clinical trials, and regulatory processes. The company trades on the OTC Markets under the ticker symbol PMCB and maintains a lean operational structure typical of early-stage biotech firms. Recent activities center on advancing its pancreatic cancer therapy through clinical development phases and exploring additional therapeutic applications for its encapsulation platform.